Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy (DERMIA)
Status:
Completed
Trial end date:
2020-04-06
Target enrollment:
Participant gender:
Summary
Clinical evidence has suggested that sub-antimicrobial doses of doxycycline may have the
potential to treat inflammatory lesions of acne. The efficacy of doses below 100 mg/day of
doxycycline in the prevention of skin toxicity in patients with treated with Epidermal Growth
Factor Receptor (EGFR)-targeted therapies has never been studied. Therefore, the aim of the
present study is to describe the efficacy of doxycycline 50 or 100 mg per day in the
prevention of skin toxicity in patients with metastatic Colorectal cancer (mCRC) treated with
anti-EGFR in combination with chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Fundacion CRIS de Investigación para Vencer el Cáncer